Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, 5.7.2016, 07:00-08:00

Maintenance work on ZORA and JDB on Tuesday, 5th July, 07h00-08h00. During this time there will be a brief unavailability for about 1 hour. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-45993

Dedes, K J; Wetterskog, D; Mendes-Pereira, A M; Natrajan, R; Lambros, M B; Geyer, F C; Vatcheva, R; Savage, K; Mackay, A; Lord, C J; Ashworth, A; Reis-Filho, J S (2010). PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Science Translational Medicine, 2(53):53ra75.

[img] PDF - Registered users only
View at publisher


PTEN (phosphatase and tensin homolog) loss of function is the most common genetic aberration in endometrioid endometrial carcinomas. In addition to its well-described role in cell signaling, PTEN is involved in the maintenance of genomic stability. Loss of PTEN function causes defects in repair of DNA double-strand breaks by homologous recombination and, therefore, sensitizes cells to inhibition of the poly(adenosine diphosphate ribose) polymerase (PARP). Here, we determined the PTEN status of eight endometrioid endometrial carcinoma cell lines and correlated it with in vitro sensitivity to the PARP inhibitor KU0058948. PTEN-deficient cells showed a significantly greater sensitivity to KU0058948 than the two endometrioid endometrial carcinoma cell lines with wild-type PTEN. The cell lines lacking PTEN expression were unable to elicit a homologous recombination damage response as assayed by RAD51 focus function (a marker of competent homologous recombination DNA repair) upon irradiation and treatment with PARP inhibitors. PTEN silencing in PTEN wild-type Hec-1b cells resulted in reduced RAD51 foci formation after DNA damage and increased sensitivity to PARP inhibition. PTEN reexpression in PTEN-null cell lines resulted in enhanced RAD51 foci formation and in relative resistance to KU0058948. Given that up to 80% of endometrioid endometrial cancers lack PTEN expression, our results suggest that PARP inhibitors may be therapeutically useful for a subset of endometrioid endometrial cancers.


44 citations in Web of Science®
85 citations in Scopus®
Google Scholar™



2 downloads since deposited on 21 Feb 2011
0 downloads since 12 months

Detailed statistics

Additional indexing

Contributors:Fink D
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:610 Medicine & health
Deposited On:21 Feb 2011 08:52
Last Modified:05 Apr 2016 14:47
Publisher:American Association for the Advancement of Science (AAAS)
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:10.1126/scitranslmed.3001538
PubMed ID:20944090

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page